Patent · US Active

Selective histone deactylase 6 inhibitors

US10227295B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignees

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS · US

Inventors

Eduardo M. Sotomayor · Tampa, US
Joel Bergman · Chicago, US
Alan P. Kozikowski · Princeton, US
Alejandro V. Villagra · Tampa, US
Karrune V. Woan · Gainesville, US

Key dates

Filing date	Sep 5, 2017
Grant date	Mar 12, 2019
Priority date	—
Expiry date	Sep 5, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D295/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.